E
Marvel Biosciences Corp. MRVL.V
TSX
Recommendation
Prev Close
$0.15
Volume
--
Avg Vol (90D)
101,071
Market Cap
$6.22M
Dividend & Yield
--
52-Week Range
$0.08 - $0.40
P/E (TTM)
--
EPS (TTM)
-$0.03
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
How Semtech’s Data Center Chips Are Powering the AI Boom
11/28/2025 - MarketBeat
Best Infrastructure Stocks To Research - December 3rd
12/3/2025 - MarketBeat
Value Stocks To Consider - December 3rd
12/3/2025 - MarketBeat
Earnings Beat: Marvell Technology Acquires Celestial AI
12/3/2025 - Zacks Investment Research
Marvell Could See AI Revenue Double By 2028 Thanks To New Tech Deal: Analysts
12/3/2025 - Benzinga
Why Is Marvell Technology (MRVL) Stock Soaring Today
12/3/2025 - StockStory Articles
Stock market hovers near all-time high on Fed rate cut expectations and retail rally
12/3/2025 - Fast Company
ASX set to edge up, Wall Street drifts near its all-time high
12/3/2025 - Sydney Morning Herald - Business
Why Marvell Technology Stock Popped Today
12/3/2025 - Fool.com Headlines
Marvell Technology (NASDAQ:MRVL) Shares Gap Up Following Better-Than-Expected Earnings
12/3/2025 - Ticker Report
JPMorgan Chase & Co. Raises Marvell Technology (NASDAQ:MRVL) Price Target to $130.00
12/3/2025 - MarketBeat
Noteworthy ETF Outflows: SOXX, LRCX, MRVL, MPWR
12/3/2025 - ETF Channel
Marvell Technology (NASDAQ:MRVL) Shares Gap Up Following Better-Than-Expected Earnings
12/3/2025 - MarketBeat
Video: Nasdaq 100 Movers: NFLX, MCHP
12/3/2025 - Market News Video
Marvell reports record Q3 revenue, raises data center growth outlook
12/3/2025 - Proactive Investors - UK
Wall Street drifts near its all-time high as Marvell Technology jumps and Macy's sinks
12/3/2025 - Orange County Register: Business
Marvell Technology (NASDAQ:MRVL) Upgraded to Buy at Summit Insights
12/3/2025 - Ticker Report
Marvell Technology Q3 Earnings Beat Estimates, Revenues Rise Y/Y
12/3/2025 - Zacks Investment Research
Wall Street Analysts Still Love Marvell, Amazon, and Broadcom
12/3/2025 - 24/7 Wall St.
Marvell Technology (MRVL) Stock Rises on Strong Data Center Outlook and New Deal
12/3/2025 - GuruFocus
Live Nasdaq Composite: Stocks Meander Amid Signals of Economic Uncertainty
12/3/2025 - 24/7 Wall St.
US stocks slip at open: Nasdaq down 0.3%, S&P dips 0.2%
12/3/2025 - Invezz News
MRVL Q3 Deep Dive: Data Center Momentum and Celestial AI Acquisition Set Growth Trajectory
12/3/2025 - StockStory Articles
Marvell Technology (MRVL) Shares Surge After Strong Q3 Earnings Beat
12/3/2025 - GuruFocus
Why These 3 Tech Stocks Could Be the Best Opportunities You're Overlooking
11/17/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$1.07M
Net Income (TTM)
-$1.59M
Balance Sheet
Total Assets (Q)
$236.10K
Total Debt (Q)
$1.67M
Total Liabilities (Q)
$3.13M
Book Value Per Share (Q)
-$0.0547
Cash Flow
Cash from Operations (TTM)
-$824.90K
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$658.30K
Net Change in Cash (TTM)
-$166.50K
Filings
Filing Date
Friday, November 28, 2025
Period Date
Monday, June 30, 2025
Next Filing
End of March (est)
Price History
Loading...
Beta
0.07
7-Day Total Return
5.71%
30-Day Total Return
-2.63%
60-Day Total Return
-22.92%
90-Day Total Return
19.35%
Year to Date Total Return
23.33%
1-Year Total Return
15.63%
2-Year Total Return
117.65%
3-Year Total Return
32.14%
5-Year Total Return
--
52-week Low
May 26, 2025 - $0.08
52-week High
Aug 29, 2025 - $0.40
Valuation
Market Cap
$6.22M - Nano Cap
Enterprise Value
$7.78M
Price/Sales (TTM)
--
Price/Book (Q)
-2.74
Dividends and Shares
Shares Outstanding
52.97
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
marvelbiotechnology.com
Phone Number
403 770 2469
Address
505 8th Avenue S.W.
Calgary, AB T2P 1G2
Country
Canada
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound... more